Patiromer utilization in patients with advanced chronic kidney disease under nephrology care in Germany.

Roberto Pecoits-Filho,Keith McCullough,Daniel Muenz,Carol Moreno Quinn,Jeff Budden,John Golden,Antonio Ramirez de Arellano,Frank-Peter Tillmann,Johannes Duttlinger,Viviane Calice-Silva,Ziad A Massy,Brian Bieber,Bruce M Robinson,Danilo Fliser,Helmut Reichel

Clinical kidney journal（2023）

引用 2|浏览23

暂无评分

摘要

Real-world evidence of patiromer use in Germany shows that, in line with what has been observed in clinical trials, patients on patiromer have a reduction in serum potassium when used long-term. Moreover, most patients on patiromer do not discontinue treatment prior to 1 year after initiation.

查看译文

关键词

chronic kidney disease,hyperkalemia,patiromer,potassium binders

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要